Clinical Trial Update: Long Term Safety and Efficacy Study of Teriflunomide 7 mg or 14 mg in Patients With Relapsing-Remitting Multiple Sclerosis [Phase 3]

View source ↗

Summary

Phase 3 long-term safety and efficacy study of teriflunomide at 7 mg and 14 mg in relapsing-remitting multiple sclerosis completed with results posted in 2017.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Relapsing-remitting Multiple Sclerosis

Drugs mentioned

• AUBAGIO (TERIFLUNOMIDE)

Snippet

Sponsor: Sanofi | Conditions: Multiple Sclerosis | Phase 3 | Status: COMPLETED | Results posted: 2017-01-30